about
AGTCystic fibrosis transmembrane conductance regulatorVasoactive intestinal polypeptideApelinAdenylate cyclase activating polypeptide 1K(lysine) acetyltransferase 2BProstaglandin D receptorUrocortinPlatelet-activating factor receptorNitric oxide synthase 3, endothelial cellEstrogen receptor 2 (beta)Gap junction protein, alpha 1Protein tyrosine phosphatase receptor type MNatriuretic peptide CCalcitonin gene-related peptide 1 (prepro)Gap junction protein alpha 5Potassium calcium-activated channel subfamily M regulatory beta subunit 1Angiotensin II receptor type 2Nitric oxide synthase 2F2R like trypsin receptor 1Epoxide hydrolase 2Serine carboxypeptidase 1Melatonin receptor 1BPhospholipase A2 group VIArachidonate 12-lipoxygenase, 12S typeINSPotassium large conductance calcium-activated channel, subfamily M, alpha member 1G protein-coupled estrogen receptor 1Arachidonate 12-lipoxygenaseProtein kinase, cGMP-dependent, type IVascular endothelial growth factor receptor 2Natriuretic peptide type CSirtuin 1Adenosine A2b receptorAlpha-2A adrenergic receptorNitric oxide synthase 2, inducibleNitric oxide synthase 1, neuronalGap junction protein, alpha 5AngiotensinogenEpidermal growth factor receptor
P682
Expression and characterization of full-length human heme oxygenase-1: the presence of intact membrane-binding region leads to increased binding affinity for NADPH cytochrome P450 reductaseInsulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway
P921
Q14859647-13CE8276-614A-4258-B741-B43ED9F39B51Q14864718-D7334366-CDA4-4C25-8287-7B8271F7E6DAQ14865072-267F0F75-84CF-46E5-B5A5-36D322E1F9A9Q14865072-C5CB2C89-4FCD-47BF-8E48-1DDCBF82A3BEQ14878242-1A52AC78-0D79-47FB-8C08-28F56185B386Q14907481-8EBF7ED4-EC84-4299-93DC-86D0EB5AC7F9Q14907481-E8862C6C-C83B-4F04-BD60-92ABA845B8DCQ14908265-200D9E89-6889-4447-9181-160E7AB5D514Q14913392-60D9B09F-37AA-4BD7-A3F4-87992FBBF303Q14916447-E25E07C0-FD12-44E2-8746-0EAFE515930AQ15320076-D54D8AC4-FE5D-4DC4-A29C-1B53EDA6B8D3Q15328616-E0280834-1C4B-41D4-98DA-02DA6EC90037Q15329166-0B1C8B14-E1DB-41B4-A91D-570AC67A27D7Q15330604-0EEB65A9-A32D-4B2E-A341-03FEF0D2CD7BQ21108320-85A8F36A-CDA4-4EE2-B823-3F8343C8E20BQ21111453-DD765548-803E-402A-96FF-27AF27D5EC2FQ21111856-0364567D-0481-4F39-B853-19A2BBBD3236Q21113152-86924C73-578C-4DD0-BE46-46EC51D5DB13Q21113525-34E8A302-2F83-4042-B7A2-4AB7A05EFE2EQ21113831-28C2187F-0E2F-4C2B-9DA1-7737242061EEQ21113831-CC2FF399-DA4C-493C-AB11-5C2C2D69D6DEQ21114547-1C75A198-1F3D-42A5-AEC0-0DE6BBF0E60EQ21115613-A609D031-FE30-4493-AAB4-ED0450E2463BQ21115613-B151867C-0CEC-47DA-BBBE-9C4FBCA337D1Q21118391-71007828-5610-4139-9E5F-CD76D1E126EBQ21122027-64A402AA-42AB-43B9-A487-88E00F37E7F9Q21122997-EAF460BC-5C91-465B-A2A4-58DAAD604BB7Q21126834-272E96C7-E96B-4470-9303-BEF3457FF81FQ21133173-67323F15-62D9-435E-A740-75FC92EEB992Q21163221-04974482-E873-4164-9622-81D2982C0151Q21491057-3F1BD2A8-C647-4C5F-93F8-6AC848A9067DQ21494462-A6574394-946B-4DCF-A4C3-794B1E2FEACFQ21494714-D0914291-F9FD-40C3-8B35-AB1410A5B582Q21495417-CF990D33-1019-4053-99FE-73FFC4E843D2Q21496011-A46DDACE-51C9-499C-B97B-2BABB886D487Q21496883-8B92B032-B126-4C5B-8520-A9A10EF391E9Q21498104-3DAC2E78-837F-4A12-9D61-7FB6591FE163Q21498709-4B601897-6611-4BD8-9280-597F6EF761B7Q21498844-8045714C-5C29-4DCA-8C8C-7C1B22ADA1DCQ21980041-5BDEBDD1-BC5A-493F-88EA-14C74E9AE088
P682
description
Any process that increases the diameter of blood vessels.
@en
biologisch proces
@nl
name
positiv regulering av blodårediameter
@nn
positive regulation of blood vessel diameter
@en
type
label
positiv regulering av blodårediameter
@nn
positive regulation of blood vessel diameter
@en
altLabel
GO:0097755
@en
prefLabel
positiv regulering av blodårediameter
@nn
positive regulation of blood vessel diameter
@en
P2888
P686
GO:0097755